Skip to Content
Merck
CN

Confirming Antibody Specificity in Xenopus.

Cold Spring Harbor protocols (2020-10-11)
Sian A Martin, Suzannah J Page, Maya Z Piccinni, Matthew J Guille
ABSTRACT

Verifying that a new antibody recognizes its target can be difficult. In this protocol, expression of a target protein in Xenopus embryos is either knocked down using CRISPR-Cas9 technology (for zygotic proteins) or enhanced by microinjection of a synthetic mRNA (for maternal proteins). Western blotting analysis is then performed. If the antibody recognizes the target protein, the western blot will show a relatively weak band for CRISPR-injected embryos and a relatively strong band for RNA-injected embryos. This represents a straightforward, powerful strategy for confirming antibody specificity in Xenopus.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
L-Cysteine, from non-animal source, BioReagent, suitable for cell culture, ≥98%